Drug Database
Back to search

Netherlands· NL-02c1feb21f9e

Ontruzant 150 mg, poeder voor concentraat voor oplossing voor infusie

A trastuzumab product containing trastuzumab, registered in Netherlands by Samsung Bioepis NL B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC L01FD01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOntruzant 150 mg, poeder voor concent…ATCL01FD01REGISTER NO.NL-02c1feb21f9ePACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about trastuzumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Trastuzumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L01FD01 (trastuzumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search trastuzumab products by name

Trastuzumab · ATC L01FD01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of trastuzumab costs, country by country.

Normalised to the WHO defined daily dose (28.6 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Trastuzumab · price per daily dose (28.6 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$116.57
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
TRASTUZUMAB
Manufacturer
Samsung Bioepis NL B.V.
Country
Netherlands (NL)
ATC code
L01FD01
ATC class
Trastuzumab
Defined daily dose
28.6 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/17/1241

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

81 interactions on record for trastuzumab.

Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check trastuzumab against other medicinesHow interaction checks work

Trastuzumab · interactions on record

81 records

  • 34 severe
  • 47 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • DoxorubicinL01DB01severe
  • DaunorubicinL01DB02severe
  • EpirubicinL01DB03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Trastuzumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All trastuzumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Dazublys, Herceptin
  • Liechtenstein · Dazublys, Herceptin
  • Norway · Dazublys, Herceptin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b5ffbb3a-cceb-419b-ba2f-bd8a17903cb6
GET /v1/drugs/b5ffbb3a-cceb-419b-ba2f-bd8a17903cb6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ontruzant-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Trastuzumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp119931",
  "excipients": [
    "HISTIDINE, (L-)",
    "HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
    "POLYSORBAAT 20 (E 432)",
    "TREHALOSE (Alpha, Alpha-)  2-WATER"
  ],
  "substances": [
    "TRASTUZUMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2017/11/15",
  "procedure_number": "EMEA/H/C/004323",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/17/1241",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about trastuzumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console